NYHETER

2017 14 sep 13:45 First North
PledPharma AB : The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group

The data safety monitoring committee gave the approval to initiate the next
cohort in the open-label, randomised, rising dose design, proof-of-principle
safety and tolerability study with Aladote in patients treated with NAC for
paracetamol overdose.

The study is conducted at the University of Edinburgh, Queen’s Medical Research
Institute in Scotland and will involve a total of 24 patients assigned into one
of 3 dosing cohorts of 8 patients.

The first cohort receiving the lowest dose of the study drug has been completed
and after reviewing the safety data the monitoring committee, in a meeting held
on September 13, approved to continue with recruitment for the middle dose
group.



For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62
Nicklas.westerholm@pledpharma.se

Michaela Gertz, CFO, phone: +46 709 26 17 75
Michaela.gertz@pledpharma.se

About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company''s most advanced project PledOx® is being developed to
reduce nerve damage associated with chemotherapy. A phase IIb study has been
conducted and will serve as the basis for the continued development. The drug
candidate Aladote® is being developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on
Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel
+46 8 463 80 00). For more information, see www.pledpharma.se